Beta Drugs credit ratios

·UnclassifiedChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025
148148—
23.023.0—
0.60×0.60×—
0.09×0.09×—
1.95×1.95×—
0.25×0.30×—
3.82×3.82×8.88×
23.7%37.7%—
As filed — company-reported covenants
——0.71×
——6.90×
——9.15×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

BETA₹1,896.00

Beta Drugs Limited

· Unclassified
₹ CrorePeersTHEJOMACPOWERSAKARSERVOTECHMcap ₹1,922 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Total Debt—147.8147.8
Net Debt—23.023.0
Total Debt/Equity—0.600.60
Net Debt/Equity—0.090.09
Total Debt/EBITDA—1.951.95
Net Debt/EBITDA—0.300.25
Interest Coverage (EBIT/Interest)8.883.823.82
Total Debt/Total Capital %—37.6523.74
As Filed — company-reported covenants
Debt/Equity (as filed)0.71——
Debt Service Coverage (as filed)6.90——
Interest Service Coverage (as filed)9.15——
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.